• +1-646-491-9876
    • +91-20-67278686

    Search

    Cedar Pollen Allergy - Pipeline Review, H1 2017

    Cedar Pollen Allergy - Pipeline Review, H1 2017

    • Report Code ID: RW0001767487
    • Category Pharmaceuticals
    • No. of Pages 34
    • Publication Month Apr-17
    • Publisher Name Global Markets Direct
    Cedar Pollen Allergy - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Cedar Pollen Allergy - Pipeline Review, H1 2017, provides an overview of the Cedar Pollen Allergy (Immunology) pipeline landscape.

    Cedar allergy is a seasonal allergy brought on by an allergic reaction to the pollen from mountain cedar trees. Symptoms include runny nose, itchy and watery eyes, nasal blockage and sneezing. Some suffers also complain of fatigue, mild headache, facial discomfort, sore throat, partial loss of smell and the sensation of ear plugging. Treatment includes antihistamines and decongestants.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Cedar Pollen Allergy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Cedar Pollen Allergy (Immunology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Cedar Pollen Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Cedar Pollen Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

    Cedar Pollen Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Cedar Pollen Allergy (Immunology) .
    - The pipeline guide reviews pipeline therapeutics for Cedar Pollen Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Cedar Pollen Allergy (Immunology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Cedar Pollen Allergy (Immunology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Cedar Pollen Allergy (Immunology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Cedar Pollen Allergy (Immunology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Cedar Pollen Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Cedar Pollen Allergy - Overview
    Cedar Pollen Allergy - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Cedar Pollen Allergy - Therapeutics Assessment
    Assessment by Route of Administration
    Assessment by Molecule Type
    Cedar Pollen Allergy - Companies Involved in Therapeutics Development
    ALK-Abello A/S
    Astellas Pharma Inc
    Japan Tobacco Inc
    REGiMMUNE Corp
    Stallergenes Greer plc
    Cedar Pollen Allergy - Drug Profiles
    ASP-4070 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Biologic for Cedar Pollen Allergy - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    JCC-LAMP-Vax - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RGI-1001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    STG-120 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TO-206 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine for Cedar Pollen Allergy - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cedar Pollen Allergy - Dormant Projects
    Cedar Pollen Allergy - Discontinued Products
    Cedar Pollen Allergy - Product Development Milestones
    Featured News & Press Releases
    Aug 07, 2015: ALK's partner for Japan reports positive Phase II/III trial results for Japanese Cedar SLIT-tablet
    Mar 09, 2015: Immunomic Therapeutics to Present at BIO-Europe Annual Conference
    Feb 20, 2015: Immunomic Therapeutics to Present Data on Its Proprietary LAMP Vaccine Platform at 2015 American Academy of Allergy, Asthma and Immunology Meeting
    Apr 24, 2013: Immunomic Therapeutics Announces Interim Data Analysis Of Phase I Study To Treat Japanese Red Cedar Allergy
    Nov 08, 2012: Immunomic Therapeutics Doses First Patient In Phase I Clinical Trial Of JRC-LAMP-Vax Vaccine To Treat Japanese Red Cedar Allergy
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Cedar Pollen Allergy, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Cedar Pollen Allergy - Pipeline by ALK-Abello A/S, H1 2017
    Cedar Pollen Allergy - Pipeline by Astellas Pharma Inc, H1 2017
    Cedar Pollen Allergy - Pipeline by Japan Tobacco Inc, H1 2017
    Cedar Pollen Allergy - Pipeline by REGiMMUNE Corp, H1 2017
    Cedar Pollen Allergy - Pipeline by Stallergenes Greer plc, H1 2017
    Cedar Pollen Allergy - Dormant Projects, H1 2017
    Cedar Pollen Allergy - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Cedar Pollen Allergy, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    ALK-Abello A/S
    Astellas Pharma Inc
    Japan Tobacco Inc
    REGiMMUNE Corp
    Stallergenes Greer plc

    Request for Sample

    Report Url http://www.reportsweb.com//cedar-pollen-allergy-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//cedar-pollen-allergy-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//cedar-pollen-allergy-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments